QSAM Biosciences, Inc. engages in the provision of nuclear medicines for the treatment of cancer and related diseases and conditions. The company is headquartered in Austin, Texas and currently employs 4 full-time employees. The company went IPO on 2011-08-25. The Company’s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC. Iso Therapeutics Group LLC is also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 and the chelant DOTMP (1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to locate the anatomical distribution. Its subsidiary is QSAM Therapeutics Inc.

Industry: Specialty Cleaning, Polishing and Sanitation Preparations Peers: Windtree Therapeutics Inc Bellerophon Therapeutics, Inc. BELLICUM PHARMACEUTICALS, INC TuHURA Biosciences Inc BIO MEDICAL AUTOMATION INC BioRestorative Therapies Inc CohBar, Inc. LogicBio Therapeutics, Inc. Unicycive Therapeutics Inc